Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2017; 71(2): 178–180. doi:10.14735/amgh2017178.

Ustekinumab – a new biological therapy for patients with Crohn’s disease

Milan Lukáš Orcid.org  1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016; 375 (20): 1946–1960.
2. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab a human interleukin 12/23 monoclonal antibody in patients with moderate to severe Crohn’s disease. Gastroenterology 2008; 135 (4): 1130–1141. doi: 10.1053/j.gastro.2008.07.014.
3. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease.  N Engl J Med 2012; 367 (16): 1519–1528. doi: 10.1056/NEJMoa1203572.
4. Battat R, Kopylov U, Bessissow T et al. Association of ustekinumab trough concentration with clinical, biochemical and endoscopic outcome. Presented at: 11th Congress of ECCO, Amsterdam 2016.
5. European medicines agency. Stelara®. [online]. Available from: http: //www.ema.europa.eu.

Credited self-teaching test